Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

AIM: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. MATERIALS & METHODS: Patients with melanoma with and without DM were matched 1:1 (2005–2016). Kaplan–Meier analysis was used to est...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlin, Nina J, Mangold, Aaron R, Amin, Shailja B, Kosiorek, Heidi E, Buras, Matthew R, Verona, Patricia M, Cook, Curtiss B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426167/
https://www.ncbi.nlm.nih.gov/pubmed/30906566
http://dx.doi.org/10.4155/fsoa-2018-0084
Descripción
Sumario:AIM: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. MATERIALS & METHODS: Patients with melanoma with and without DM were matched 1:1 (2005–2016). Kaplan–Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A(1c) (HbA(1c)) and glucose measures over time. RESULTS: Mean HbA(1c) during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81–99%) for patients with DM and 63% (95% CI: 51–79%) for patients without DM (p = 0.02). CONCLUSION: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM.

Ejemplares similares